Analysts Set Expectations for Immatics FY2025 Earnings

Immatics N.V. (NASDAQ:IMTX) – Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for shares of Immatics in a research report issued on Thursday, August 14th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings per share of ($2.15) for the year, down from their prior forecast of ($1.40). The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share. Cantor Fitzgerald also issued estimates for Immatics’ FY2026 earnings at ($1.55) EPS.

A number of other analysts have also issued reports on IMTX. Wall Street Zen lowered Immatics from a “hold” rating to a “strong sell” rating in a report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft assumed coverage on Immatics in a report on Wednesday, May 28th. They set a “buy” rating and a $10.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Immatics has an average rating of “Moderate Buy” and an average price target of $14.67.

Immatics Stock Up 7.3%

IMTX opened at $6.33 on Monday. The firm has a market capitalization of $769.41 million, a P/E ratio of -9.74 and a beta of 0.93. The stock’s 50 day moving average price is $6.03 and its two-hundred day moving average price is $5.20. Immatics has a 12-month low of $3.30 and a 12-month high of $13.09.

Immatics (NASDAQ:IMTX) last released its earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.28). The business had revenue of $6.48 million during the quarter, compared to analyst estimates of $13.05 million. Immatics had a negative net margin of 59.29% and a negative return on equity of 15.60%.

Institutional Trading of Immatics

Several institutional investors have recently modified their holdings of IMTX. Guggenheim Capital LLC acquired a new stake in shares of Immatics during the 4th quarter worth approximately $101,000. Marshall Wace LLP bought a new position in shares of Immatics during the 4th quarter worth approximately $409,000. T. Rowe Price Investment Management Inc. lifted its position in shares of Immatics by 43.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,604,777 shares of the company’s stock worth $75,400,000 after buying an additional 3,225,141 shares during the period. Virtus ETF Advisers LLC lifted its position in shares of Immatics by 34.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company’s stock worth $68,000 after buying an additional 2,479 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Immatics by 31.5% during the 4th quarter. Northern Trust Corp now owns 47,226 shares of the company’s stock worth $336,000 after buying an additional 11,304 shares during the period. Institutional investors and hedge funds own 64.41% of the company’s stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.